Zobrazeno 1 - 10
of 248
pro vyhledávání: '"J Klupp"'
Autor:
Ulf Neumann, Matthias Glanemann, C Radtke, G. Junge, Jan M. Langrehr, Marcus Bahra, J Klupp, Peter Neuhaus, R. Pfitzmann, Ruth Neuhaus
Publikováno v:
Clinical Transplantation. 20:272-283
Background: The addition of mycophenolate mofetil (MMF) to the induction protocol resulted in a lower incidence of rejection episodes. However, the question whether MMF should be administered in combination with tacrolimus or cyclosporine has not bee
Publikováno v:
Best Practice & Research Clinical Gastroenterology. 19:637-648
Patients with neuroendocrine tumours often present with synchronous liver metastases or develop hepatic metastases in the course of their disease. A complete removal of liver metastases with an intention to cure may be accomplished by liver resection
Autor:
J Klupp, Andreas Pascher
Publikováno v:
BioDrugs. 19:211-231
Tumor necrosis factor (TNF)-alpha inhibitors have proven efficacy in various autoimmune diseases such as Crohn disease, rheumatoid arthritis, psoriasis, and ankylosing spondylitis. Indeed, some TNFalpha inhibitors have already been approved for the m
Publikováno v:
Digestive Diseases. 23:65-71
Portal hypertension is a complication of liver cirrhosis that may itself cause complications such as variceal bleeding, ascites and hepatorenal syndrome. There are several options for symptomatic treatment including drug therapy, endoscopy, transjugu
Autor:
T Kraus, C Graeb, Peter Neuhaus, F Iberer, J Klupp, D Candinas, D Faust, M Wolff, Andrea R. Müller, Markus Golling, C Zülke, Wolf O. Bechstein, Thomas E. Becker, C Broelsch, Lutz Fischer, Edward K. Geissler, Christian P. Strassburg
Publikováno v:
Zeitschrift für Gastroenterologie. 42:1333-1340
Sirolimus is an m-TOR inhibitor without renal side effects and potentially protects against the development of malignancy. Due to a higher incidence of complications in two trials and an official warning in the drug information, the use of Sirolimus
Publikováno v:
Transplant Immunology, 9, 211-214. Elsevier
Within the field of solid organ transplantation there is an unprecedented interest in therapeutic drug monitoring of immunosuppressive drugs. Ideally therapeutic drug monitoring should cost-effectively lead to improved efficacy of the drug and to a r
Autor:
I. Krishnan, Andreas Pascher, J. Klupp, Johann Pratschke, E Salamé, H Isoneimi, M Bijarnia, Jacques Pirenne, P De Simone
Publikováno v:
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 15(5)
Efficacy and safety of protein kinase C inhibitor sotrastaurin (STN) with tacrolimus (TAC) was assessed in a 24-month, multicenter, phase II study in de novo liver transplant recipients. A total of 204 patients were randomized (1:1:1:1) to STN 200 mg
Autor:
J Klupp, H. Keck, S. Meuer, A. Radtke, Thomas Steinmüller, Sven Jonas, Peter Neuhaus, Olaf Guckelberger, U. Neumann, M. Knoop, H.-P. Lemmens, Jan M. Langrehr, H Schlag, N. Nüssler, Hartmut Lobeck, Wolf O. Bechstein, R Lohmann
Publikováno v:
Transplantation. 63:1772-1781
Background. Quadruple immunosuppressive induction therapy has been shown to markedly reduce the incidence of acute rejection episodes without increasing the incidence of infectious complications after liver transplantation. However, the use of polycl
Autor:
Josette Eris, Stefan Vitko, J. M. Campistol, U. Gopalakrishnan, Graeme R. Russ, Klemens Budde, J. Klupp, Marcia Kho, Lionel Rostaing, Arndt Hartmann, Helio Tedesco-Silva, I. Krishnan
Publikováno v:
American Journal of Transplantation, 13(7), 1757-1768. Wiley-Blackwell Publishing Ltd
Sotrastaurin, a novel selective protein-kinase-C inhibitor, inhibits early T cell activation via a calcineurin-independent pathway. Efficacy and safety of sotrastaurin in a calcineurin inhibitor-free regimen were evaluated in this two-stage Phase II
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2535d306de889b0eb10200094b72b669
https://pure.eur.nl/en/publications/68f4c2b4-4b63-479e-a789-e429ac0da00e
https://pure.eur.nl/en/publications/68f4c2b4-4b63-479e-a789-e429ac0da00e
Autor:
Andrea R. Müller, Peter Neuhaus, Ulrich Frei, Andreas Kahl, D Kampf, M Oppert, J Klupp, U Settmacher, J Lepenies
Publikováno v:
Transplantation Proceedings. 34:2253-2255